---
title: "Sinopharm sells 30.13% stake in Guorui Pharma to Shanghai Shyndec for RMB 240.07 million"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296367279.md"
description: "Sinopharm Group agreed to sell its 30.13% stake in Guorui Pharmaceutical to Shanghai Shyndec for RMB 240.07 million. Subsidiaries Sinopharm (CNCM) and CNPGC will sell 12.06% and 8.81% respectively. The transaction values Guorui at RMB 796.79 million, with total consideration of RMB 406.36 million. Guorui will be deconsolidated; Sinopharm retains a 49% indirect stake via CNCM. A disposal gain of approximately RMB 45 million is expected, with proceeds earmarked for working capital."
datetime: "2026-08-19T14:00:07.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296367279.md)
  - [en](https://longbridge.com/en/news/296367279.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296367279.md)
generator: "portal-rs"
---

# Sinopharm sells 30.13% stake in Guorui Pharma to Shanghai Shyndec for RMB 240.07 million

-   Sinopharm Group agreed to sell its 30.13% stake in Guorui Pharmaceutical to Shanghai Shyndec for RMB 240.07 million. \* Group subsidiary Sinopharm (CNCM) will sell 12.06% for RMB 96.09 million; CNPGC will sell 8.81% for RMB 70.2 million. \* The combined 51% transfer values Guorui at RMB 796.79 million; total consideration RMB 406.36 million. \* Guorui will be deconsolidated; Sinopharm will hold no direct stake, while Sinopharm (CNCM) will retain 49%. \* The group preliminarily expects a disposal gain of about RMB 45 million; proceeds earmarked for working capital. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sinopharm Group Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260819-12291116), on August 19, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [01099.HK](https://longbridge.com/en/quote/01099.HK.md)
- [000028.CN](https://longbridge.com/en/quote/000028.CN.md)
- [600420.CN](https://longbridge.com/en/quote/600420.CN.md)

## Related News & Research

- [CICC Keeps Their Buy Rating on Sinopharm Group Co (SHTDF)](https://longbridge.com/en/news/284328826.md)
- [Sinopharm Group Co (SHTDF) Gets a Buy from CLSA](https://longbridge.com/en/news/284466436.md)
- [Warren Buffett's Successor, Greg Abel, Has 34.7% of Berkshire Hathaway's Portfolio Invested in These 2 Artificial Intelligence (AI) Stocks](https://longbridge.com/en/news/296274565.md)
- [Hengrui Pharma launches RMB 1 billion-RMB 2 billion A-share buyback, caps price at RMB 81.78](https://longbridge.com/en/news/296368941.md)
- [Billionaire Activist Investor Dan Loeb’s Anti-Buffett Trade — Third Point Buys This Stock as Berkshire Hathaway Slashes Its Major Stake](https://longbridge.com/en/news/296685842.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**